TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04533789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
Study: NCT03583008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) Intervention--Academic Detailing
Description: One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) Intervention--Prescribing Practices
Description: Education and support related to anticoagulant prescribing practices.
Study: NCT01932697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Description: Undergo hyperfractionated IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo hyperfractionated IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01474850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung recruitment maneuver
Description: RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
Study: NCT04001088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Dosing regimen of one capsule daily for a maximum of 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing regimen of one capsule daily for a maximum of 48 weeks.
Study: NCT00738647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restorations with composite
Description: The cavity is excavated and filled according to the guidelines for composite restorations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth restorations with composite
Description: The cavity is excavated and filled according to the guidelines for composite restorations
Study: NCT00132080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
Study: NCT04664257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
Study: NCT03994978

Intervention type: PROCEDURE
Intervention: elective sigmoidectomy
Description: elective sigmoidectomy
Study: NCT02167438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-Avert Perianal Stabilizer
Study: NCT02026765

Intervention type: DEVICE
Group type: OTHER
Intervention: traditional lens
Description: A random eyes with traditional lens

Intervention type: DEVICE
Group type: OTHER
Intervention: heparin surface modified aspheric lens
Description: the other eye implant heparin surface modified aspheric lens
Study: NCT03172728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-education pamphlet
Description: psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
Study: NCT02314858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Personalized Video (BPV)
Description: The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Personalized Video (NPV)
Description: The NPV group will see a stock video of someone with OSA.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The TAU group will not watch a video.
Study: NCT00850369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: Study subjects will receive monthly transfusions with 2 units of red blood cells
Study: NCT03175081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Study: NCT04518618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
Study: NCT02691546

Intervention type: OTHER
Intervention: blood sample collection
Study: NCT04448275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics Nerve flossing
Description: Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected exercise program
Description: Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional selected exercise program
Description: Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
Study: NCT04572828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block
Description: Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block
Description: Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg Naproxen Sodium 60 minutes before the procedure
Description: 550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The capped needle
Description: The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
Study: NCT03573596

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
Study: NCT03743766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
Study: NCT01116752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)
Description: In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)
Description: In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
Study: NCT04179279

Intervention type: DEVICE
Intervention: Gili Biosensor System (Gili Pro Biosensor)
Description: Non-contact monitoring of heart and respiratory rates using an optical device

Intervention type: DEVICE
Intervention: Gili Biosensor System (Gili Pro Biosensor)
Description: Non-contact monitoring of heart and respiratory rates using an optical device
Study: NCT01870947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genetic and Biomarkers
Description: Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genetic and Biomarkers
Description: Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
Study: NCT04300465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 week MySlainte Program
Description: The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí.
Study: NCT02459457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Cisplatin
Description: patients get Paclitaxel and Cisplatin according to protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Fluorouracil
Description: patients get Paclitaxel and Fluorouracil according to protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: patients get Paclitaxel and Carboplatin according to protocol

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 34Fx

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 34Fx

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 34Fx
Study: NCT03900910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric cancer prevention
Description: Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric cancer prevention
Description: Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of the program
Description: Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of the program
Description: Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
Study: NCT04545333

Intervention type: DIAGNOSTIC_TEST
Intervention: clonoSEQ Assay
Description: minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: clonoSEQ Assay
Description: minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: clonoSEQ Assay
Description: minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: clonoSEQ Assay
Description: minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
Study: NCT03452852

Intervention type: DEVICE
Group type: OTHER
Intervention: PICO
Description: NPWT with PICO (Smith and Nephew)

Intervention type: OTHER
Group type: OTHER
Intervention: Coban 2 lite
Description: Compression bandaging with Coban 2 lite
Study: NCT03862677

Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no intervention
Study: NCT03240653

Intervention type: OTHER
Intervention: Stratified response to Enzyme Therapy
Description: Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.

Intervention type: OTHER
Intervention: Stratified response to Enzyme Therapy
Description: Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
Study: NCT03711292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic Stewardship
Description: For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
Study: NCT02799394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity modification, exercises and gradual return to sport
Study: NCT01998789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tacrolimus
Description: Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.
Study: NCT01531777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: 750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT00795275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Phosphate
Description: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Phosphate
Description: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
Study: NCT00842244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
Study: NCT02469142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADM tension-free hernia reparation
Description: Use ADM as opposed to nothing to repair incarcerated inguinal hernia
Study: NCT00669877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study: NCT01208064

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00669877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.